# Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC

> **NCT06863311** · PHASE2 · RECRUITING · sponsor: **Karie Runcie** · enrollment: 70 (estimated)

## Conditions studied

- Advanced Renal Cell Carcinoma
- Metastatic Renal Cell Carcinoma
- Clear Cell Renal Cell Carcinoma

## Interventions

- **DRUG:** XL092
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT06863311
- **Lead sponsor:** Karie Runcie
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-13
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-05-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06863311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06863311, "Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06863311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*